FDA advisory panels are set to resume with fresh meetings tied to previously contested applications. Under new leadership, the agency indicated it would place renewed emphasis on advisory meetings for contentious product submissions, and new announcements now outline specific dates and targets. Replimune’s proposed oncolytic immunotherapy RP1, a twice-rejected advanced melanoma candidate seeking accelerated approval, is scheduled for an advisory committee encounter in late July as part of the agency’s reconsideration. Separately, Capricor’s meeting also returns to the agenda amid lingering questions from earlier review periods. For biopharma, the operational takeaway is that disputed evidence packages may face additional public scrutiny before final FDA action, with potential downstream effects on timelines, label negotiations, and investor expectations.